Drug device combination is defined as the combination of drugs and medical devices that can be chemically or physically united or co-packaged as separate, cross labeled products. The commercialization cycle from R&D to product shows the immense potential of bundled offering. Currently, the market has a potential of US$10.6 billion and has been experiencing a growth of 15% CAGR for past two years. In the next five years, the market is expected to grow at a CAGR of 11.8%.
Comments